Related Experiment Videos
Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours
M A Knowles1, N Hornigold, E Pitt
1Cancer Research UK Clinical Centre, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, UK. margaret.knowles@cancer.org.uk
Biochemical Society Transactions
|May 30, 2003
Summary
Tuberous sclerosis genes TSC1/TSC2 mutations are linked to hamartomas but not common cancers. However, TSC1 mutations in bladder cancer and deletions in other cancers suggest a role in sporadic tumor development.
Area of Science:
- Oncology
- Cancer Genetics
Background:
- Tuberous sclerosis complex (TSC) genes TSC1 and TSC2 inactivation causes hamartomas in TSC patients.
- Despite this, TSC patients lack increased risk for common adult solid cancers.
- Dysregulation of the phosphoinositide 3-kinase pathway, involving TSC genes, is implicated in various malignancies.
Purpose of the Study:
- To investigate the role of TSC1 and TSC2 gene inactivation in sporadic cancers.
- To analyze TSC1 mutations in bladder cancer and explore TSC gene deletions in other epithelial cancers.
Main Methods:
- Analysis of TSC1 mutation spectrum in bladder cancer.
- Functional studies using TSC1 gene-replacement in bladder tumor cells.
- Review of literature for genetic alterations in sporadic epithelial cancers, focusing on 16p13 and 9q34 regions.
Main Results:
- TSC1 mutations were identified in bladder cancer.
- Significant deletions in the 16p13 and 9q34 regions, encompassing TSC genes, were found in ovarian, gallbladder, and non-small-cell lung cancers.
Conclusions:
- TSC gene inactivation may contribute to sporadic cancer development, particularly bladder cancer.
- Further mutation analyses of TSC genes are warranted in ovarian, gallbladder, and lung cancers due to observed deletions.